Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481318 | 0.91 | CHRM2 (0.53) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL7539952 | 0.80 | ALDH1A1 (0.45) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL2550556 | 0.79 | LMNA (0.68) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL20481400 | 0.78 | LMNA (0.71) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL2870098 | 0.78 | LMNA (0.71) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL7448825 | 0.78 | KDM4E (0.45) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL19026256 | 0.76 | LMNA (0.48) | KMT2AMEN1ALDH1A1LMNAPKM | |
| SCHEMBL15063194 | 0.76 | TSHR (0.62) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL13789612 | 0.76 | CHRM2 (0.53) | CHRM2CHRM1CHRM3KMT2AMEN1 | |
| SCHEMBL15063297 | 0.76 | MAOB (0.55) | CHRM2CHRM1CHRM3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4159727-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Morphic Therapeutic, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2018160521-A2 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | Lazuli, Inc. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CHRM2 1783/4885CHRM1 2383/4885CHRM3 1447/4885 |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CHRM2 1783/4885CHRM1 2383/4885CHRM3 1447/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | CHRM2 3153/4885CHRM1 3917/4885CHRM3 2839/4885 |
| US-20200087299-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGAV, ITGA6 | CHRM2 1643/4885CHRM1 1821/4885CHRM3 1264/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CHRM2 2084/4885CHRM1 2563/4885CHRM3 1646/4885 |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CHRM2 1783/4885CHRM1 2383/4885CHRM3 1447/4885 |
| US-20180244648-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | CHRM2 1783/4885CHRM1 2383/4885CHRM3 1447/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | CHRM2 1783/4885CHRM1 2383/4885CHRM3 1447/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | CHRM2 2084/4885CHRM1 2563/4885CHRM3 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.